Evidence map›Paper›PMID 29987026›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence.

Ruian Ke, Hui Li, Shuyi Wang, Wenge Ding, Ruy M Ribeiro, Elena E Giorgi, Tanmoy Bhattacharya, Richard J O Barnard, Beatrice H Hahn, George M Shaw and 1 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ruian KeDepartment of Mathematics, North Carolina State University, Raleigh, NC 27695.
Hui LiDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Shuyi WangDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Wenge DingDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Ruy M RibeiroTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545.ORCID 0000-0002-3988-8241
Elena E GiorgiTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545.
Tanmoy BhattacharyaTheoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545.ORCID 0000-0002-1060-652X
Richard J O BarnardDepartment of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ 07033.
Beatrice H HahnDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104; bhahn@pennmedicine.upenn.edu asp@lanl.gov.
George M ShawDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Alan S PerelsonTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545; bhahn@pennmedicine.upenn.edu asp@lanl.gov.

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6M
Spatial Models of Intrahepatic Hepatitis C Virus Propagation in HumansR01AI116868 · NIAID · TRIAD NATIONAL SECURITY, LLC · PI ASHWIN BALAGOPAL, Ruy M Ribeiro · 2016 to 2026
$8.5M
Scientific CoreU19AI088791 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 2010 to 2020
$8.2M
Collaborative Integration of HCV Molecular Virology and Mathematical ModelingR01AI078881 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PERELSON, ALAN S, UPRICHARD, SUSAN L. · 2011 to 2025
$7.5M
Modeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0M
Immune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7M
NIAID NIH HHS P30 AI045008NIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI078881NIAID NIH HHS R01 AI116868NIAID NIH HHS U19 AI088791NIH HHS R01 OD011095
6 · The paper itself

Abstract

RNA viruses exist as a genetically diverse quasispecies with extraordinary ability to adapt to abrupt changes in the host environment. However, the molecular mechanisms that contribute to their rapid adaptation and persistence in vivo are not well studied. Here, we probe hepatitis C virus (HCV) persistence by analyzing clinical samples taken from subjects who were treated with a second-generation HCV protease inhibitor. Frequent longitudinal viral load determinations and large-scale single-genome sequence analyses revealed rapid antiviral resistance development, and surprisingly, dynamic turnover of dominant drug-resistant mutant populations long after treatment cessation. We fitted mathematical models to both the viral load and the viral sequencing data, and the results provided strong support for the critical roles that superinfection and cure of infected cells play in facilitating the rapid turnover and persistence of viral populations. More broadly, our results highlight the importance of considering viral dynamics and competition at the intracellular level in understanding rapid viral adaptation. Thus, we propose a theoretical framework integrating viral and molecular mechanisms to explain rapid viral evolution, resistance, and persistence despite antiviral treatment and host immune responses.

Indexed as

Adaptation, PhysiologicalDrug Resistance, ViralHepacivirusHepatitis CModels, BiologicalAntiviral AgentsHumansAntiviral Agentshepatitis C virusmathematical modelingphylodynamic modelingvirus evolutionvirus persistence

Identifiers

PMID29987026
PMCPMC6065014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.